Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 32, Issue 5, 2012, Pages 351-361

  De Souza, Andrea Silveira ^a,b,e   De Oliveira Souza, Ricardo ^a,b,c   Moll, Jorge ^a,b   Tovar Moll, Fernanda ^a,b,d   Andreiuolo, Pedro Angelo ^a,b   Bottino, Cássio M C ^b,e,f  

^a D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^b Gaffrée e Guinle University Hospital   (Brazil)

^c Institut Philippe Pinel de Montreal   (Canada)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e Institute and Department of Psychiatry   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer dementia; Alzheimer's disease; Clinical assessment; Cognitive analysis; Diagnostic criteria; Magnetic resonance spectroscopy; Mild cognitive impairment

Indexed keywords

CREATINE; INOSITOL; N ACETYLASPARTIC ACID; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ADULT; AGED; ALZHEIMER DISEASE; AMNESTIC MILD COGNITIVE IMPAIRMENT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRY; PARIETAL CORTEX; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; CINGULATE GYRUS; CLASSIFICATION; DAILY LIFE ACTIVITY; DIFFERENTIAL DIAGNOSIS; MENTAL HEALTH; METABOLISM; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARIETAL LOBE; PREDICTIVE VALUE; REFERENCE VALUE; TEMPORAL LOBE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASPARTIC ACID; CREATINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GYRUS CINGULI; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MENTAL STATUS SCHEDULE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; TEMPORAL LOBE;

EID: 84856569446     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000334656     Document Type: Article

References (92)

1. Bottino CM, Azevedo D, Tatsch M, Hototian SR, Moscoso MA, Folquitto J, Scalco AZ, Bazzarella MC, Lopes MA, Litvoc J: Estimate of dementia prevalence in a community sample from São Paulo, Brazil. Dement Geriatr Cogn Disord 2008; 26: 291-299.
2. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E: The consortium to establish a registry for Alzheimer's disease (CERAD). XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995; 45: 1451-1455.
3. Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E: Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-489. (Pubitemid 30647242)
4. Nitrini R, Caramelli P, Herrera E, Bahia VS, Caixeta LF, Radanovic M, Anghinah R, Charchat-Fichman H, Porto CS, Carthery MT, Hartmann APJ, Huang N, Smid J, Lima EP, Takada LT, Takahashi DY: Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2004; 18: 241-246. (Pubitemid 40076156)
5. Kornhuber J, Schmidtke K, Frölich L, Perneczky R, Wolf S, Hampel H, Jessen F, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hüll M, Gertz H-J, Schröder J, Pantel J, Rienhoff O, Seuchter SA, Rüther E, Henn F, Maier W, Wiltfang J: Early and differential diagnosis of dementia and mild cognitive impairment. Design and cohort baseline characteristics of the German dementia competence network. Dement Geriatr Cogn Disord 2009; 27: 404-417.
6. Wimo A, Jonsson L, Winblad B: An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21: 175-181. (Pubitemid 43201328)
7. Bickel H, Kurz A: Education, occupation, and dementia: The Bavarian school sisters study. Dement Geriatr Cogn Disord 2009; 27: 548-556.
8. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF: Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994; 51: 1198-1204. (Pubitemid 24369608)
9. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
10. Dubois B, Feldman HH, Jacova C, De Kosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746. (Pubitemid 47058377)
11. Cummings JL, Kaufer D: Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996; 47: 876-883.
12. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, De Kosky ST: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
13. Diniz BS, Nunes PV, Yassuda MS, Forlenza OV: Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study. Dement Geriatr Cogn Disord 2009; 27: 224-231.
14. Rivas-Vasquez RA, Mendez C, Rey GJ, Carrazana EJ: Mild cognitive impairment: New neuropsychological and pharmacological target. Arch Clin Neuropsychol 2004; 19: 11-27. (Pubitemid 37518325)
15. Chao LL, Schuff N, Kramer JH, Du AT, Capizzano AA, O'Neill J, Wolkowitz OM, Jagust WJ, Chui HC, Miller BL, Yaffe K, Weiner MW: Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005; 64: 282-289.
16. Firbank MJ, Harrison RM, O'Brien JT: A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002; 14: 64-76. (Pubitemid 36152947)
17. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R: In vivo magnetic resonance spectroscopy of human brain: The biophysical basis of dementia. Biophys Chem 1997; 68: 161-172. (Pubitemid 28064663)
18. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD: Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65-72.
19. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
20. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;ii:1457-1459. (Pubitemid 9061468)
21. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR: Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-1500. (Pubitemid 36559525)
22. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman B: Neuronal loss correlates but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24. (Pubitemid 27057088)
23. Hof PR, Bierer LM, Perl DP, Delacourte A, Buée L, Bouras C, Morrison JH: Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-yearold patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques. Arch Neurol 1992; 49: 946-953.
24. Huesgen CT, Burger PC, Crain BJ, Johnson GA: In vitro MR microscopy of the hippocampus in Alzheimer's disease. Neurology 1993; 43: 145-152. (Pubitemid 23035373)
25. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A: Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000; 355: 1696-1697. (Pubitemid 30248487)
26. Jessen F, Block W, Träber F, Keller E, Flacke S, Lamerichs R, Schild HH, Heun R: Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001; 57: 930-932. (Pubitemid 32845528)
27. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB: Brain metabolite concentration and dementia severity in Alzheimer's disease: A 1 H MRS study. Neurology 2001; 57: 626-632. (Pubitemid 32782989)
28. Jessen F, Block W, Träber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000; 55: 684-688.
29. Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC: Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease. A 1 H MRS study. Neurology 2000; 55: 210-217. (Pubitemid 30604620)
30. Kwo-On-Yuen PF, Newmark RD, Budinger TF, Kaye JA, Ball MJ, Jagust WJ: Brain Nacetyl-L-aspartic acid in Alzheimer's disease: A proton magnetic resonance spectroscopy study. Brain Res 1994; 667: 167-174.
31. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD: Alzheimer disease: Depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993; 187: 433-437. (Pubitemid 23127850)
32. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, Weiner MW: Alzheimer disease: Quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology 1998; 207: 91-102. (Pubitemid 28168672)
33. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO: In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 1999; 56: 185-192. (Pubitemid 29081394)
34. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text revision (DSM-IV-TR). Washington, American Psychiatric Association, 2000, pp 147-171.
35. Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, Eustache F: In vivo mapping of gray matter loss with voxelbased morphometry in mild Alzheimer's disease. Neuroimage 2001; 14: 298-309. (Pubitemid 32709545)
36. Chételat G, Landeau B, Eustache F, Mézenge F, Viader F, de la Sayette V, Desgranges B, Baron JC: Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study. Neuroimage 2005; 27: 934-946. (Pubitemid 41317262)
37. Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, Asada T, Iwabuchi S, Samejima H: Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 2005; 382: 269-274. (Pubitemid 40733634)
38. Jones BF, Barnes J, Uylings HBM, Fox NC, Frost C, Witter MP, Scheltens P: Differential regional atrophy of the cingulated gyrus in Alzheimer disease: A volumetric MRI study. Cereb Cortex 2006; 16: 1701-1708. (Pubitemid 44729908)
39. Zhang Y, Schuff N, Jahng G-H, Bayne BS, Mori S, Schad L, Mueller S, Du A-T, Kramer JH, Yaffe K, Chui H, Jagust WJ, Miller BL, Weiner MW: Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007; 68: 13-19. (Pubitemid 46058544)
40. Catani M, Schotten MT: A diffusion tensor imaging tractography atlas for virtual in vivo dissections. Cortex 2008; 44: 1105-1132.
41. Wakana S, Jiang H, Nagae-Poetscher LM, Zijl PCM, Mori S: Fiber tract-based atlas of human white matter anatomy. Radiology 2004; 230: 77-87. (Pubitemid 37549786)
42. Bonte FJ, Harris TS, Roney CA, Hynan LS: Differential diagnosis between Alzheimer's and frontoparietal disease by the posterior cingulated sign. J Nucl Med 2004; 45: 771-774. (Pubitemid 47618555)
43. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94. (Pubitemid 27304784)
44. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer's disease in persons homozygous for the4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-758. (Pubitemid 26089356)
45. Small GW, Ercoli LM, Silverman DHS, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. PNAS 2000; 97: 6037-6042. (Pubitemid 30367519)
46. Petrella JR, Coleman RE, Doraiswamy PM: Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. Radiology 2003; 226: 315-336. (Pubitemid 36313415)
47. Meguro K, LeMestric C, Landeau B, Desgranges B, Eustache F, Baron J: Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: A PET/MRI correlative study. J Neurol Neurosurg Psychiatry 2001; 71: 315-321. (Pubitemid 32772527)
48. Chételat G, Villain N, Desgranges B, Eustache F, Baron J-C: Posterior cingulated hypometabolism in early Alzheimer's disease: What is the contribution of local atrophy versus disconnection? Brain 2009; 132: 1-2.
49. Garden DL, Massey PV, Caruana DA, Johnson B, Warburton EC, Aggleton JP, Bashir ZL: Anterior thalamic lesions stop synaptic plasticity in retrosplenial cortex slices: Expanding the pathology of diencephalic amnesia. Brain 2009; 132: 1847-1857.
50. Villain N, Desgranges B, Viader F, de la Sayette V, Mézenge F, Landeau B, Baron JC, Eustache F, Chételat G: Relationships between hippocampal atrophy, white matter disruption and gray matter hypometabolism in Alzheimer's disease. J Neurosci 2008; 28: 6174-6181.
51. Castillo M, Kwock L, Mukherji SK: Clinical applications of proton MR spectroscopy. AJNR 1996; 17: 1-15. (Pubitemid 26024702)
52. Kantarci K, Xu YC, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR Jr: Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14: 198-207. (Pubitemid 36151487)
53. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992. (Pubitemid 33143977)
54. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34: 939-943.
55. Berg L: Mild senile dementia of the Alzheimer type: Diagnostic criteria and natural history. Mount Sinai J Med 1988; 55: 87-96. (Pubitemid 18047095)
56. Morris JC: The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993; 43: 2412-2413.
57. Duyckaerts C, Hauw JJ, Piette F, Rainsard C, Poulain V, Berthaux P, Escourolle R: Cortical atrophy in senile dementia of the Alzheimer type is mainly due to a decrease in cortical length. Acta Neuropathol (Berl) 1985; 66: 72-74. (Pubitemid 15138012)
58. Terry RD, Hansen LA, De Teresa R, Davies P, Tobias H, Katzman R: Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp Neurol 1987; 46: 262-268. (Pubitemid 17069792)
59. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementias. Arch Neurol 1975; 32: 632-637.
60. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42: 631-639.
61. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP: Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995; 52: 81-88.
62. De Kosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 1990; 27: 457-464. (Pubitemid 20149963)
63. Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
64. Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT: Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-4500. (Pubitemid 26243044)
65. Reisberg B: Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24: 653-659. (Pubitemid 19054371)
66. Reisberg B, Pattscgull-Furlan A, Franssen E, Sclan SG, Kluger A, Dingcong L, Ferris SH: Dementia of the Alzheimer type recapitulates ontogeny inversely on specific ordinal and temporal parameters; in Kostovic I, Knezevic S, Wisniewski HM, Spillich GJ (eds): Neurodevelopment, aging and cognition. Boston, Birkhäuser, 1992, pp 345-369.
67. Sclan SG, Reisberg B: Functional assessment staging (FAST) in Alzheimer's disease: Reliability, validity, and ordinality. Int Psychogeriatr 1992; 4: 55-69.
68. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
69. Grigoletto F, Zappalà G, Anderson DW, Lebowitz BD: Norms for the Mini-Mental State Examination in a healthy population. Neurology 1999; 53: 315-320. (Pubitemid 29344353)
70. Nelson A, Fogel BS, Faust D: Bedside cognitive screening instruments. A critical assessment. J Nerv Ment Dis 1986; 174: 73-83. (Pubitemid 16189801)
71. Kachigan SK: Multivariate Statistical Analysis: A Conceptual Introduction, ed 2. New York, Radius Press, 1991.
72. Bisquerra R, Sarriera JC, Martínez F: Introdução à estatística: Enfoque informático com o pacote estatístico SPSS. Porto Alegre, Artmed, 2004.
73. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82; 239-259.
74. Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR: Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol 1986; 20: 472-481. (Pubitemid 16005665)
75. Whitwell JL, Przybelski SA, Weingand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR: 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007; 130: 1777-1786. (Pubitemid 47343806)
76. Pearson RCA, Esiri MM, Hiorns RW, Wilcock GK, Powell TP: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985; 82: 4531-4534. (Pubitemid 15233154)
77. Folstein MF: Differential diagnosis of dementia. The clinical process. Psychiatr Clin North Am 1997; 20: 45-57. (Pubitemid 27118415)
78. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr: Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: Comparison of 1.5 and 3.0 T. AJNR 2003; 24: 843-849. (Pubitemid 36617413)
79. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G, Pelliccioli GP, Senin U: Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997; 97: 9-14. (Pubitemid 27279860)
80. Miller BL: A review of chemical issues in 1 H NMR spectroscopy: N-acetyl-aspartate, creatine and choline. NMR Biomed 1991; 4: 47-52.
81. Simmons M, Frondoza C, Coyle J: Immunocytochemical localization of N-acetyl-L-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
82. Tsai G, Coyle J: N-acetylaspartate in neuropsychiatry disorders. Prog Neurobiol 1995; 46: 531-540.
83. Soares DP, Law M: Magnetic resonance spectroscopy of the brain: Review of metabolites and clinical applications. Clin Radiol 2009; 64: 12-21.
84. Ross B, Michaelis T: MR spectroscopy of the brain: Neurospectroscopy; in Edelman RR, Zlatkin MB, Hesselink JR (eds): Clinical Magnetic Resonance Imaging. Philadelphia, Saunders, 1996, pp 928-981.
85. Valenzuela MJ, Sachdev P: Magnetic resonance spectroscopy in AD. Neurology 2001; 56: 592-598. (Pubitemid 32209990)
86. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, Brück W: Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR 1999; 20: 1619-1627. (Pubitemid 29498612)
87. De Stefano N, Matthews D, Arnold D: Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34: 721-727.
88. Rango M, Spagnoli D, Tomei G, Bamonti F, Scarlato G, Zetta L: Central nervous system trans-synaptic effects of acute axonal injury: A 1 H magnetic resonance spectroscopy study. Magn Reson Med 1995; 33: 595-600.
89. Ernst T, Chang L, Melchor R, Mehringer CM: Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203: 829-836. (Pubitemid 27227438)
90. Engelhardt E, Moreira DM, Laks J, Cavalcanti JLS: Alzheimer's disease and proton magnetic resonance spectroscopy of limbic regions. A suggestion of a clinical-spectroscopic staging. Arq Neuropsiquiatr 2005; 63: 195-200. (Pubitemid 40834710)
91. Brambati SM, Belleville S, Kergoat M-J, Chayer C, Gauthier S, Joubert S: Single-and multiple-domain amnestic mild cognitive impairment: Two sides of the same coin? Dement Geriatr Cogn Disord 2009; 28: 541-549.
92. Moats RA, Shonk T: Evaluation of automated MR spectroscopy: Application in Alzheimer disease. AJNR 1995; 16: 1779-1782.